Detalhe da pesquisa
1.
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Future Oncol
; 15(31): 3531-3545, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31516032
2.
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Blood
; 119(16): 3698-704, 2012 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22389254
3.
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Leukemia
; 37(10): 2017-2026, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37604981
4.
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Lancet Haematol
; 4(1): e24-e34, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27914971
5.
T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens.
Biol Blood Marrow Transplant
; 13(3): 265-76, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17317580
6.
T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease.
Biol Blood Marrow Transplant
; 12(8): 818-27, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16864052